Bevacizumab and etoposide combination chemotherapy in patients with recurrent malignant gliomas who failed bevacizumab

摘要: Bevacizumab is the current standard of care treatment for recurring malignant glioma patients. However, most tumors become resistant to bevacizumab, and there no standardized, effective chemotherapy patients after bevacizumab failure. Retrospective chart review was performed in order identify treated with oral, metronomic etoposide combination being diagnosed progressive disease while on bevacizumab. This approved by Institutional Review Board (IRB) University California, Irvine. Six gliomas met inclusion criteria. The median progression-free survival (PFS) anaplastic astrocytoma (AA) eight months, overall 28 months. two Glioblastoma Multiforme (GBM) showed tumor progression four weeks etoposide, died within months beginning etoposide/bevacizumab regimen. In this limited study, AA demonstrated prolonged control oral despite initial These results may warrant further investigation a prospective clinical trial who developed resistance